Home> Products> robust glycemic control

{ "products": [ { "_id": "66619278db9fdd21801ef284", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "SEIZMET TRIO 0.3 ", "description": "SEIZMET TRIO 0.3 \nGlimepiride (2mg), Metformin SR (500mg), Voglibose (0.3mg)\nIntroduction to SEIZMET TRIO 0.3\nSEIZMET TRIO 0.3 is a combination medication that includes Glimepiride 2mg, Metformin Hydrochloride Sustained Release (SR) 500mg, and Voglibose 0.3mg. This medication is primarily used for the management of type 2 diabetes mellitus. By combining the complementary mechanisms of Glimepiride, Metformin, and Voglibose, SEIZMET TRIO 0.3 offers comprehensive glycemic control, helping patients manage their blood sugar levels effectively.\n\nWhat are Glimepiride, Metformin, and Voglibose?\nOverview of Glimepiride\nGlimepiride is a sulfonylurea that helps control blood sugar levels by stimulating the pancreas to release more insulin. It works by closing ATP-sensitive potassium channels in the pancreatic beta cells, leading to insulin secretion.\n\nOverview of Metformin\nMetformin is a biguanide that helps lower blood sugar levels by improving the body's sensitivity to insulin and reducing the amount of glucose produced by the liver. It also enhances peripheral glucose uptake and utilization. The sustained-release formulation ensures a prolonged effect throughout the day.\n\nOverview of Voglibose\nVoglibose is an alpha-glucosidase inhibitor that helps control blood sugar levels by slowing the digestion and absorption of carbohydrates in the small intestine. This leads to a slower and lower rise in blood glucose levels after meals.\n\nBenefits of SEIZMET TRIO 0.3\nEffective Blood Sugar Management\nTriple Mechanism of Action: Glimepiride stimulates insulin secretion, Metformin improves insulin sensitivity and reduces hepatic glucose production, and Voglibose slows carbohydrate absorption. This comprehensive approach offers robust glycemic control.\nPostprandial and Fasting Glucose Control: This combination helps manage both postprandial (after-meal) and fasting blood sugar levels, offering all-around glycemic control.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: SEIZMET TRIO 0.3 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, SEIZMET TRIO 0.3 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nAdditional Health Benefits\nWeight Management: Metformin is often associated with weight neutrality or modest weight loss, making it a favorable option for overweight or obese patients.\nImproved Glycemic Control: Voglibose’s action on slowing carbohydrate absorption leads to better control over postprandial spikes, contributing to overall glycemic stability.\nHow to Use SEIZMET TRIO 0.3\nDosage and Administration\nRecommended Dosage: The typical dosage of SEIZMET TRIO 0.3 is one tablet taken once or twice daily, depending on your healthcare provider's instructions. The dosage may be adjusted based on individual response and blood sugar levels.\nAdministration: Take the tablet with meals to reduce the risk of gastrointestinal discomfort and enhance the effectiveness of Metformin and Voglibose. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take SEIZMET TRIO 0.3 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/seizmet-trio-0-3-133446", "price": 166.9, "discountamount": 50.07, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "3", "day", "body", "Diet", "EMAIL", "Order", "liver", "water", "meals", "amount", "slower", "option", "Action", "Support", "Overview", "pancreas", "readings", "digestion", "biguanide", "Voglibose", "one tablet", "lower rise", "overweight", "Guidelines", "full glass", "neuropathy", "utilization", "Adjustments", "information", "retinopathy", "Optimal Use", "Introduction", "Metformin SR", "SEIZMET TRIO", "best results", "sterisonline", "Reduced Risk", "instructions", "sterispharma", "sulfonylurea", "effectiveness", "CALL/WHATSAPP", "carbohydrates", "Administration", "obese patients", "typical dosage", "treatment plan", "Consistent Use", "Glimepiride 2mg", "small intestine", "Exercise Adjunct", "prolonged effect", "Triple Mechanism", "excellent adjunct", "Weight Management", "weight neutrality", "insulin secretion", "Recommended Dosage", "modest weight loss", "blood sugar control", "Diabetes Management", "individual response", "postprandial spikes", "healthcare provider", "insulin sensitivity", "blood glucose levels", "pancreatic beta cells", "cardiovascular disease", "combination medication", "comprehensive approach", "Fasting Glucose Control", "long-term complications", "robust glycemic control", "lifestyle modifications", "carbohydrate absorption", "type 2 diabetes mellitus", "complementary mechanisms", "peripheral glucose uptake", "stable blood sugar levels", "hepatic glucose production", "Additional Health Benefits", "overall glycemic stability", "alpha-glucosidase inhibitor", "gastrointestinal discomfort", "sustained-release formulation", "comprehensive glycemic control", "ATP-sensitive potassium channels", "Effective Blood Sugar Management", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1453, "imageuri": "https://productimages.withfloats.com/actual/6661927b487c46164ce4b1f6.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661927b487c46164ce4b1f6.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T10:42:00.595Z", "updatedon": "2024-06-29T07:23:34.909Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/seizmet-trio-0-3-/1453", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "SEIZMET TRIO 0.3 ", "category": "DIABETIC RANGE", "tags": [ "SEIZMET TRIO 0.3", "Glimepiride (2mg)", "Metformin SR (500mg)", "Voglibose (0.3mg)", "Glimepiride 2mg side effects", "glimepiride + metformin", "Glimepiride 2mg price", "Glimepiride 2mg Uses in Hindi" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "666191664515df1748621e0b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "SEIZMET TRIO 0.2 ", "description": "SEIZMET TRIO 0.2 \nGlimepiride (2mg), Metformin SR (500mg), Voglibose (0.2mg)\nIntroduction to SEIZMET TRIO 0.2\nSEIZMET TRIO 0.2 is a combination medication that includes Glimepiride 2mg, Metformin Hydrochloride Sustained Release (SR) 500mg, and Voglibose 0.2mg. This medication is primarily used for the management of type 2 diabetes mellitus. By combining the complementary mechanisms of Glimepiride, Metformin, and Voglibose, SEIZMET TRIO 0.2 offers comprehensive glycemic control, helping patients manage their blood sugar levels effectively.\n\nWhat are Glimepiride, Metformin, and Voglibose?\nOverview of Glimepiride\nGlimepiride is a sulfonylurea that helps control blood sugar levels by stimulating the pancreas to release more insulin. It works by closing ATP-sensitive potassium channels in the pancreatic beta cells, leading to insulin secretion.\n\nOverview of Metformin\nMetformin is a biguanide that helps lower blood sugar levels by improving the body's sensitivity to insulin and reducing the amount of glucose produced by the liver. It also enhances peripheral glucose uptake and utilization. The sustained-release formulation ensures a prolonged effect throughout the day.\n\nOverview of Voglibose\nVoglibose is an alpha-glucosidase inhibitor that helps control blood sugar levels by slowing the digestion and absorption of carbohydrates in the small intestine. This leads to a slower and lower rise in blood glucose levels after meals.\n\nBenefits of SEIZMET TRIO 0.2\nEffective Blood Sugar Management\nTriple Mechanism of Action: Glimepiride stimulates insulin secretion, Metformin improves insulin sensitivity and reduces hepatic glucose production, and Voglibose slows carbohydrate absorption. This comprehensive approach offers robust glycemic control.\nPostprandial and Fasting Glucose Control: This combination helps manage both postprandial (after-meal) and fasting blood sugar levels, offering all-around glycemic control.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: SEIZMET TRIO 0.2 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, SEIZMET TRIO 0.2 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nAdditional Health Benefits\nWeight Management: Metformin is often associated with weight neutrality or modest weight loss, making it a favorable option for overweight or obese patients.\nImproved Glycemic Control: Voglibose’s action on slowing carbohydrate absorption leads to better control over postprandial spikes, contributing to overall glycemic stability.\nHow to Use SEIZMET TRIO 0.2\nDosage and Administration\nRecommended Dosage: The typical dosage of SEIZMET TRIO 0.2 is one tablet taken once or twice daily, depending on your healthcare provider's instructions. The dosage may be adjusted based on individual response and blood sugar levels.\nAdministration: Take the tablet with meals to reduce the risk of gastrointestinal discomfort and enhance the effectiveness of Metformin and Voglibose. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take SEIZMET TRIO 0.2 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/seizmet-trio-0-2-133445", "price": 155.9, "discountamount": 46.77, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "Diet", "body", "liver", "meals", "water", "Order", "EMAIL", "option", "amount", "slower", "Action", "Support", "readings", "Overview", "pancreas", "Improved", "Voglibose", "digestion", "biguanide", "neuropathy", "full glass", "lower rise", "overweight", "one tablet", "Guidelines", "information", "Adjustments", "retinopathy", "utilization", "Optimal Use", "Metformin SR", "best results", "Introduction", "SEIZMET TRIO", "sterisonline", "Reduced Risk", "instructions", "sterispharma", "sulfonylurea", "effectiveness", "CALL/WHATSAPP", "carbohydrates", "Administration", "obese patients", "typical dosage", "treatment plan", "Consistent Use", "Glimepiride 2mg", "small intestine", "Exercise Adjunct", "prolonged effect", "Triple Mechanism", "excellent adjunct", "Weight Management", "weight neutrality", "insulin secretion", "Recommended Dosage", "modest weight loss", "blood sugar control", "Diabetes Management", "individual response", "postprandial spikes", "healthcare provider", "insulin sensitivity", "blood glucose levels", "pancreatic beta cells", "cardiovascular disease", "combination medication", "comprehensive approach", "Fasting Glucose Control", "long-term complications", "robust glycemic control", "lifestyle modifications", "carbohydrate absorption", "type 2 diabetes mellitus", "complementary mechanisms", "peripheral glucose uptake", "stable blood sugar levels", "hepatic glucose production", "Additional Health Benefits", "overall glycemic stability", "alpha-glucosidase inhibitor", "gastrointestinal discomfort", "sustained-release formulation", "comprehensive glycemic control", "ATP-sensitive potassium channels", "Effective Blood Sugar Management", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1452, "imageuri": "https://productimages.withfloats.com/actual/6661916a8e77bb2c7156e563.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661916a8e77bb2c7156e563.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T10:37:26.597Z", "updatedon": "2024-06-29T07:23:47.697Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//seizmet-trio-0-2-/1452", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "SEIZMET TRIO 0.2 ", "category": "DIABETIC RANGE", "tags": [ "SEIZMET TRIO 0.2", "Glimepiride (2mg)", "Metformin SR (500mg)", "Voglibose (0.2mg)", "Glimepiride 2mg side effects", "glimepiride + metformin", "Glimepiride 2mg price", "Glimepiride 2mg Uses in Hindi" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "665efdbd66170d1ff8cb13bf", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLIDAPA 3D 10/100/500 SR ", "description": "GLIDAPA 3D 10/100/500 SR \nDapaflozin 10 mg, Sitagliptin 100 mg & Metformin SR 500 mg\nIntroduction\nGLIDAPA 3D 10/100/500 SR is a sophisticated, multi-mechanism oral medication designed for the management of Type 2 diabetes. It combines Dapagliflozin (10 mg), Sitagliptin (100 mg), and Metformin (500 mg, sustained release), offering a robust, integrated approach to controlling high blood glucose levels.\n\nMechanism of Action\n\nDapagliflozin (10 mg): As an SGLT2 inhibitor, Dapagliflozin promotes the excretion of glucose through urine by blocking its reabsorption in the kidneys. This helps to lower blood sugar levels and also has benefits for weight loss and cardiovascular health.\nSitagliptin (100 mg): A DPP-4 inhibitor, Sitagliptin works by enhancing the body's own ability to lower blood glucose levels in response to meals. It does this by increasing the levels of incretin hormones, which affect the pancreas to produce more insulin and less glucagon.\nMetformin SR (500 mg): Metformin works primarily by reducing glucose production in the liver, improving insulin sensitivity, and lowering glucose absorption in the gut. The sustained-release (SR) formulation ensures a steady release over time, minimizing gastrointestinal side effects and maintaining more consistent blood sugar control.\nBenefits\nGLIDAPA 3D 10/100/500 SR provides a comprehensive treatment solution by addressing several key pathways in glucose metabolism, thereby reducing the risk of both hyperglycemia and associated complications. The combination of these three active substances in a single formulation enhances convenience and potentially improves adherence to treatment protocols.\n\nDosage and Administration\n\nDosage: The recommended starting dose depends on the patient’s current treatment regimen and their specific health profile. Adjustments should be made based on effectiveness and tolerability, under the guidance of a healthcare professional.\nAdministration: This medication should be taken once daily in the morning, with or without food. The tablet should be swallowed whole to maintain the sustained release of Metformin.\nSide Effects\nPossible side effects of GLIDAPA 3D 10/100/500 SR include urinary tract and genital infections (due to Dapagliflozin), nausea or a sore throat (from Sitagliptin), and digestive issues such as diarrhea or abdominal pain (common with Metformin). Most side effects are manageable and tend to decrease over time.\n\nConclusion\nGLIDAPA 3D 10/100/500 SR is a versatile and effective option for those managing Type 2 diabetes, offering triple-action treatment in one convenient medication. It targets various aspects of diabetes management, improves glycemic control, and enhances overall quality of life. Patients are advised to maintain regular follow-ups with their healthcare provider to optimize treatment outcomes and manage any side effects.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/glidapa-3d-10-100-500-sr-134215", "price": 575.0, "discountamount": 172.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "gut", "time", "life", "risk", "food", "body", "urine", "liver", "EMAIL", "Order", "meals", "500 mg", "nausea", "tablet", "patient", "ability", "kidneys", "morning", "response", "diarrhea", "pancreas", "guidance", "benefits", "adherence", "versatile", "excretion", "Conclusion", "sore throat", "Sitagliptin", "weight loss", "Adjustments", "combination", "information", "convenience", "Introduction", "sterispharma", "Metformin SR", "reabsorption", "sterisonline", "urinary tract", "CALL/WHATSAPP", "hyperglycemia", "Dapagliflozin", "less glucagon", "effectiveness", "starting dose", "abdominal pain", "steady release", "overall quality", "SGLT2 inhibitor", "various aspects", "Type 2 diabetes", "DPP-4 inhibitor", "Dapaflozin 10 mg", "effective option", "digestive issues", "glycemic control", "Most side effects", "sustained release", "incretin hormones", "regular follow-ups", "genital infections", "blood sugar levels", "glucose metabolism", "glucose absorption", "glucose production", "treatment outcomes", "single formulation", "diabetes management", "insulin sensitivity", "healthcare provider", "treatment protocols", "several key pathways", "Administration Dosage", "Possible side effects", "cardiovascular health", "triple-action treatment", "specific health profile", "three active substances", "healthcare professional", "associated complications", "GLIDAPA 3D 10/100/500 SR", "current treatment regimen", "one convenient medication", "high blood glucose levels", "robust, integrated approach", "gastrointestinal side effects", "consistent blood sugar control", "comprehensive treatment solution", "sustained-release (SR) formulation", "sophisticated, multi-mechanism oral medication" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1300, "imageuri": "https://productimages.withfloats.com/actual/665efdc0e874b19df8b5f4ce.png", "tileimageuri": "https://productimages.withfloats.com/tile/665efdc0e874b19df8b5f4ce.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-04T11:42:53.803Z", "updatedon": "2024-06-04T11:42:53.803Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glidapa-3d-10-100-500-sr-/1300", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIDAPA 3D 10/100/500 SR ", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "665ef5bda743fd235821deeb", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGLAZE M 80 ", "description": "GLICLAGLAZE M 80 \ngliclazide (80mg),Metformin (500 mg)\nIntroduction\nGLICLAGLAZE M 80 is a specialized medication formulated for individuals diagnosed with Type 2 diabetes, aiming to enhance blood sugar regulation. This oral medication combines Gliclazide (80 mg) with Metformin (500 mg), two effective antidiabetic agents that provide a synergistic effect to control high blood sugar.\n\nMechanism of Action\n\nGliclazide (80 mg): Belonging to the sulfonylurea class, Gliclazide works by increasing insulin secretion from the pancreatic beta cells. It promotes a decrease in blood glucose levels and enhances the action of insulin in the body. Additionally, Gliclazide improves blood flow and has protective effects against the vascular complications of diabetes.\nMetformin (500 mg): Metformin reduces hepatic glucose production and improves insulin sensitivity by enhancing peripheral glucose uptake, particularly in muscle cells. This action helps lower blood glucose levels without the risk of inducing hypoglycemia and is associated with a potential reduction in body weight.\nBenefits\nGLICLAGLAZE M 80 offers a robust approach to managing Type 2 diabetes by targeting different aspects of the disease. The combination of Gliclazide and Metformin in this medication helps to control blood sugar more effectively than either component alone, potentially lowering the patient's risk of diabetes-related complications.\n\nDosage and Administration\n\nDosage: The starting dose should be adjusted based on the patient’s previous medication regimen, effectiveness, and tolerability. Dose adjustments should be made based on glycemic control, as assessed by regular monitoring of blood glucose levels.\nAdministration: It is recommended to take GLICLAGLAZE M 80 with meals to maximize drug absorption and minimize potential gastrointestinal side effects.\nSide Effects\nPotential side effects of GLICLAGLAZE M 80 include gastrointestinal symptoms like nausea and diarrhea, which usually improve over time. The risk of hypoglycemia exists but is moderated by the inclusion of Metformin.\n\nConclusion\nGLICLAGLAZE M 80 represents an effective treatment solution for managing Type 2 diabetes, combining two powerful antidiabetic agents to improve glycemic control and reduce the risk of diabetes complications. Patients should maintain regular consultations with their healthcare provider to tailor their treatment plan according to their specific needs, ensuring the best possible outcomes in diabetes management.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/gliclaglaze-m-80-133420\n\n\n\n\n\n", "price": 137.0, "discountamount": 41.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "risk", "time", "Order", "meals", "EMAIL", "nausea", "500 mg", "Action", "patient", "disease", "diarrhea", "Benefits", "decrease", "Mechanism", "Metformin", "component", "inclusion", "Conclusion", "blood flow", "gliclazide", "individuals", "information", "body weight", "combination", "Introduction", "muscle cells", "tolerability", "sterispharma", "hypoglycemia", "sterisonline", "starting dose", "effectiveness", "CALL/WHATSAPP", "GLICLAGLAZE M", "treatment plan", "specific needs", "Type 2 diabetes", "oral medication", "robust approach", "drug absorption", "high blood sugar", "Dose adjustments", "glycemic control", "different aspects", "insulin secretion", "regular monitoring", "sulfonylurea class", "synergistic effect", "protective effects", "healthcare provider", "insulin sensitivity", "potential reduction", "diabetes management", "blood glucose levels", "regular consultations", "pancreatic beta cells", "Administration Dosage", "best possible outcomes", "blood sugar regulation", "Potential side effects", "specialized medication", "diabetes complications", "vascular complications", "gastrointestinal symptoms", "peripheral glucose uptake", "hepatic glucose production", "previous medication regimen", "effective treatment solution", "diabetes-related complications", "two powerful antidiabetic agents", "two effective antidiabetic agents", "potential gastrointestinal side effects" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1287, "imageuri": "https://productimages.withfloats.com/actual/665ef5c0ca75628a5853ff45.png", "tileimageuri": "https://productimages.withfloats.com/tile/665ef5c0ca75628a5853ff45.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-04T11:08:45.584Z", "updatedon": "2024-06-04T11:08:45.584Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//gliclaglaze-m-80-/1287", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGLAZE M 80 ", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68d51d9a26579f4bc195771a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Glimepiride IP1 mg, Voglibose IP 0.2 MG & Metformin Hydrochloride IP 500 mg ", "description": "GLIMITERIS MV1 0.2 is an advanced fixed-dose combination (FDC) medication designed for adults with Type 2 Diabetes Mellitus (T2DM) who require more than lifestyle modifications or single/dual therapy to maintain optimal blood sugar levels. This innovative formulation brings together the power of three well-established antidiabetic agents—Glimepiride (1 mg), Voglibose (0.2 mg), and Metformin Hydrochloride SR (500 mg)—to provide comprehensive glycemic control.\n\nIt is particularly effective for patients struggling with postprandial hyperglycemia, fasting glucose regulation, and HbA1c reduction, making it a preferred choice in cases of poorly controlled diabetes.\n\n \n\nMechanism of Action\nThe therapeutic benefit of GLIMITERIS MV1 0.2 comes from the unique synergy of its three components, each targeting different aspects of glucose metabolism:\n\n1. Glimepiride (1 mg) – Sulfonylurea\nStimulates insulin secretion by activating pancreatic beta cells.\n\nProvides a long-lasting effect with comparatively lower hypoglycemia risk than older sulfonylureas.\n\nHelps reduce both fasting and postprandial glucose levels.\n\n2. Voglibose (0.2 mg) – Alpha-Glucosidase Inhibitor\nDelays the breakdown and absorption of carbohydrates in the intestine.\n\nMinimizes post-meal glucose spikes (PPBG).\n\nActs locally in the gut and has minimal systemic absorption, which reduces systemic side effects.\n\n3. Metformin Hydrochloride SR (500 mg) – Biguanide\nDecreases hepatic glucose production (gluconeogenesis).\n\nImproves peripheral insulin sensitivity, enhancing glucose uptake in muscles.\n\nDoes not cause hypoglycemia on its own.\n\nThe sustained-release (SR) formulation ensures extended control and reduces gastrointestinal side effects.\n\n \n\nIndications\nGLIMITERIS MV1 0.2 is indicated for:\n\nAdults with Type 2 Diabetes Mellitus.\n\nPatients inadequately controlled with monotherapy or dual therapy.\n\nManagement of fasting and postprandial hyperglycemia.\n\nLong-term HbA1c reduction as part of a comprehensive diabetes care plan.\n\n \n\nKey Benefits\n✅ Comprehensive Blood Sugar Control – Acts on fasting, post-meal, and long-term HbA1c levels.\n✅ Postprandial Spike Management – Voglibose effectively controls carbohydrate-induced sugar surges.\n✅ Reduced Pill Burden – Combines three medicines into a single tablet.\n✅ Lower Hypoglycemia Risk – Metformin and Voglibose balance out Glimepiride’s insulin-secreting effect.\n✅ Weight Management Support – Metformin may promote modest weight loss or prevent weight gain.\n✅ Improved Tolerability – SR formulation of Metformin enhances gastrointestinal comfort.\n\n \n\nDosage and Administration\nRecommended dose: One tablet once or twice daily with meals, or as directed by the physician.\n\nAdministration tips:\n\nTake with the first bite of a main meal to maximize Voglibose’s effect.\n\nSwallow whole with water; do not crush or chew the SR tablet.\n\nDose adjustments: Based on blood sugar monitoring, clinical response, and renal/hepatic function.\n\n \n\nContraindications\nGLIMITERIS MV1 0.2 is not suitable for patients with:\n\nType 1 diabetes or diabetic ketoacidosis.\n\nSevere renal impairment (eGFR <30 mL/min/1.73 m²).\n\nHepatic dysfunction.\n\nSevere gastrointestinal diseases.\n\nHistory of lactic acidosis.\n\nHypersensitivity to Glimepiride, Voglibose, or Metformin.\n\nPregnancy and lactation (unless strictly advised by a physician).\n\n \n\nWarnings and Precautions\nHypoglycemia: Risk is higher when combined with other antidiabetics or with missed meals.\n\nLactic Acidosis: A rare but life-threatening effect of Metformin—renal function monitoring is essential.\n\nGI Side Effects: Voglibose and Metformin may cause bloating, flatulence, or diarrhea (usually temporary).\n\nVitamin B12 Monitoring: Long-term Metformin use may reduce B12 absorption.\n\nLiver and Kidney Function: Regular monitoring is recommended for safe long-term use.\n\n \n\nAdverse Effects\nCommon:\nGlimepiride: Mild hypoglycemia, dizziness, slight weight gain.\n\nVoglibose: Gas, abdominal discomfort, mild diarrhea.\n\nMetformin SR: Nausea, bloating, metallic taste, loose stools.\n\nRare but Serious:\nLactic acidosis (from Metformin).\n\nSevere hypoglycemia (especially if meals are skipped).\n\nAllergic reactions such as rash, itching, or swelling.\n\nElevated liver enzymes.\n\nSeek medical attention if symptoms such as rapid breathing, confusion, severe fatigue, or muscle pain occur.\n\n \n\nDrug Interactions\nIncreased hypoglycemia risk: With insulin, beta-blockers, and sulfonylureas.\n\nReduced Metformin efficacy: With corticosteroids, estrogens, and diuretics.\n\nLactic acidosis risk: Higher with alcohol or iodinated contrast agents. ", "price": 263.0, "discountamount": 80.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2182, "imageuri": "https://productimages.withfloats.com/actual/68d51d9cdf1a4ca2c252370a.png", "tileimageuri": "https://productimages.withfloats.com/tile/68d51d9cdf1a4ca2c252370a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-25T10:46:50.098Z", "updatedon": "2025-10-02T11:20:20.402Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glimepiride-ip1-mg-voglibose-ip-0-2-mg-metformin-hydrochloride-ip-500-mg-/2182", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIMITERIS MV1 0.2", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68b0256b813270ffac595cb0", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRELAQWK 100", "description": "TRELAQWK 100 is an advanced oral antidiabetic medication containing Trelagliptin 100 mg, specifically designed for adults with type 2 diabetes mellitus (T2DM). Belonging to the class of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, this formulation helps improve blood glucose control when used along with a proper diet and regular exercise.\nWith its once-weekly dosage regimen, TRELAQWK 100 offers a convenient treatment option, enhancing patient compliance and simplifying long-term diabetes management.\nKey Ingredient\nTrelagliptin 100 mg\nA long-acting DPP-4 inhibitor that regulates blood glucose levels by enhancing incretin hormones. These incretins stimulate insulin secretion and suppress glucagon release, helping to achieve better glycemic control.\nKey Benefits of TRELAQWK 100\nWeekly dosing ensures greater convenience and adherence\nReduces both fasting and postprandial blood sugar levels\nSupports natural blood sugar regulation without weight gain\nLow risk of hypoglycemia, especially when used as monotherapy or with non-insulin therapies\nCan be prescribed as monotherapy or in combination with other antidiabetic agents like metformin or sulfonylureas\nHow TRELAQWK 100 Works\nTRELAQWK 100 functions by blocking the DPP-4 enzyme, which normally degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).\nThese incretin hormones:\nStimulate insulin secretion in response to meals\nReduce glucagon release, lowering blood sugar levels\nThanks to its extended half-life, trelagliptin allows for once-weekly dosing, unlike other DPP-4 inhibitors that require daily administration.\nDirections for Use\nDosage: Take one tablet of TRELAQWK 100 once weekly, or as directed by your physician\nAdministration: May be taken with or without food, ideally on the same day each week\nMissed dose: Do not double the dose; consult your healthcare provider for guidance\nPossible Side Effects\nTRELAQWK 100 is usually well-tolerated, but some individuals may experience:\nMild headache\nNasopharyngitis (common cold-like symptoms)\nConstipation\nUpper respiratory tract infections\nRare skin allergies (rash, itching)\n👉 If you experience persistent abdominal pain, severe rashes, or symptoms suggestive of pancreatitis, stop the medication and seek medical care immediately.", "price": 550.0, "discountamount": 165.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2166, "imageuri": "https://productimages.withfloats.com/actual/68b0256ebb42c3d551ad314c.png", "tileimageuri": "https://productimages.withfloats.com/tile/68b0256ebb42c3d551ad314c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-28T09:46:19.602Z", "updatedon": "2025-08-28T09:46:19.602Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-100/2166", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "trelagliptin 100 mg", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68b02393f5434d48fca8b8ca", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRELAQWK 50", "description": "TRELAQWK 50 is a modern oral antidiabetic tablet containing Trelagliptin 50 mg, specially developed for adults with type 2 diabetes mellitus. This once-weekly medication helps regulate blood sugar effectively, offering both convenience and strong clinical outcomes. With its advanced formulation, TRELAQWK 50 supports better glycemic control, making it easier for patients to lead a balanced and healthier lifestyle.\nManufactured under strict quality standards, TRELAQWK 50 ensures patient compliance, long-term safety, and efficacy in diabetes management.\nKey Ingredient\nTrelagliptin (50 mg):\nA unique, long-acting DPP-4 (dipeptidyl peptidase-4) inhibitor that allows weekly dosing, ensuring higher treatment adherence while maintaining effective control over blood glucose levels.\nKey Benefits of TRELAQWK 50\nProvides consistent blood sugar management with just one tablet per week\nEnhances insulin secretion while lowering glucagon levels in a glucose-dependent manner\nHelps reduce both fasting and postprandial blood glucose\nConvenient choice for patients with busy schedules who struggle with daily tablets\nLow risk of hypoglycemia when used as monotherapy\nSupports long-term improvement in HbA1c levels\nMechanism of Action – How TRELAQWK 50 Works\nTRELAQWK 50 works by blocking the DPP-4 enzyme, which normally degrades incretin hormones such as GLP-1 and GIP. These incretins are vital for maintaining blood sugar balance. By prolonging incretin activity, trelagliptin:\nStimulates insulin secretion from the pancreas\nReduces glucagon release from alpha cells\nHelps lower blood sugar, particularly after meals\nThis mechanism provides both effective glycemic control and improved patient compliance.\nDirections for Use\nTake one tablet of TRELAQWK 50 once a week, on the same day each week\nCan be taken with or without food\nSwallow whole with a glass of water\nFollow your doctor’s advice for dosage adjustment\nDo not double the dose if missed; consult your healthcare provider\nPossible Side Effects\nTRELAQWK 50 is usually well-tolerated. However, some patients may experience:\nMild headache\nNasopharyngitis (cold-like symptoms)\nDiarrhea\nStomach discomfort or indigestion\nRare allergic reactions (rash, itching)\nIf any unusual or persistent side effects occur, seek medical advice promptly.", "price": 375.0, "discountamount": 112.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2165, "imageuri": "https://productimages.withfloats.com/actual/68b023971624ba892ffd8c69.png", "tileimageuri": "https://productimages.withfloats.com/tile/68b023971624ba892ffd8c69.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-28T09:38:27.036Z", "updatedon": "2025-08-28T09:38:27.036Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-50/2165", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "trelagliptin 50 mg", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6890aa548a215c65672372e1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "EMPATECH LINA 25/5", "description": "EMPATECH LINA 25/5 is a pharmaceutical tablet containing a combination of two active ingredients: Empagliflozin 25MG and Linagliptin 5MG. This medication is designed to help manage blood sugar levels in adults with type 2 diabetes mellitus. The combination works through complementary mechanisms to improve glycemic control more effectively than either drug alone. Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that promotes the excretion of excess glucose through urine, while Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and suppresses glucagon release, particularly after meals. EMPATECH LINA 25/5 is generally prescribed alongside a balanced diet and regular exercise to optimize blood sugar management and reduce the risk of diabetes-related complications such as kidney damage, neuropathy, and cardiovascular issues.\n\nWhat is EMPATECH LINA 25/5?\n\nEMPATECH LINA 25/5 is a prescription medication combining Empagliflozin (25MG) and Linagliptin (5MG) tablets used to manage type 2 diabetes. It helps control elevated blood sugar levels by using dual actions — the removal of glucose via kidneys and improving pancreatic hormone responses. This combination aims to achieve better and sustained glycemic control, often necessary for patients who have inadequate blood sugar control with other treatments.\n\nUses of EMPATECH LINA 25/5\n\nTo improve blood sugar control in adults with type 2 diabetes, particularly when monotherapy is insufficient.\n\nOften used as a second-line therapy after metformin or when metformin is not tolerated.\n\nTo reduce HbA1c (hemoglobin A1c), an important measure of long-term glucose control.\n\nMay help reduce weight and blood pressure as empagliflozin aids in glucose excretion.\n\nSupports comprehensive diabetes management along with diet and exercise.\n\nPrevents or reduces the risk of diabetes-associated complications such as kidney disease, cardiovascular events, and nerve damage.\n\nSide Effects of EMPATECH LINA 25/5\n\nCommon side effects may include urinary tract infections and genital infections due to increased glucose in urine.\n\nIncreased urination and dehydration.\n\nDizziness or lightheadedness, especially when standing up quickly.\n\nHypoglycemia (low blood sugar), though rare with this combination.\n\nGastrointestinal symptoms such as nausea or diarrhea.\n\nPotential increased risk of ketoacidosis (a serious condition related to high blood acids) in rare cases.\n\nAllergic reactions, although uncommon, may occur and require prompt medical attention.\n\nPrecautions Before Using EMPATECH LINA 25/5\n\nInform your healthcare provider if you have kidney disease, liver problems, or a history of urinary tract infections.\n\nNot recommended for type 1 diabetes or diabetic ketoacidosis treatment.\n\nUse with caution if you are pregnant, planning to become pregnant, or breastfeeding.\n\nStay hydrated while on this medication to reduce the risk of dehydration and dizziness.\n\nInform your doctor about any history of pancreatitis or pancreas disorders.\n\nRegular monitoring of kidney function and blood sugar levels is advised during treatment.\n\nAvoid drinking excessive alcohol as it may increase side effects or risk of ketoacidosis.\n\nDrug Interactions: What Drugs Interact with EMPATECH LINA 25/5?\n\nOther antidiabetic medications, such as insulin or sulfonylureas, may increase the risk of hypoglycemia.\n\nDiuretics, blood pressure medications, and lithium may interact and increase side effects.\n\nDrugs that impair kidney function can affect empagliflozin’s efficacy and safety.\n\nCertain enzyme-inducing drugs may reduce linagliptin levels, lowering its effectiveness.\n\nConsult your healthcare provider for a full list of possible interactions and before starting any new medication, including over-the-counter drugs or supplements.\n\nConclusion\n\nEMPATECH LINA 25/5, containing Empagliflozin 25MG and Linagliptin 5MG, is an effective combination medication to treat high blood sugar levels caused by type 2 diabetes. Its dual-action approach targets different physiological mechanisms to improve blood glucose control, helping reduce the risks and complications associated with diabetes. While it is generally well-tolerated, awareness of possible side effects and drug interactions is important. Always use under medical supervision, alongside lifestyle modifications such as diet and exercise, for optimal diabetes management.", "price": 345.0, "discountamount": 104.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2154, "imageuri": "https://productimages.withfloats.com/actual/6890aa58dd0bc098c3220f4c.png", "tileimageuri": "https://productimages.withfloats.com/tile/6890aa58dd0bc098c3220f4c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-04T12:40:52.619Z", "updatedon": "2025-08-04T12:40:52.619Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empatech-lina-25-5/2154", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Empagliflozin and Linagliptin Tablets", "category": "DIABETIC RANGE", "tags": [ "Empagliflozin and Linagliptin Tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68822dd35b399ba6097ed11b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "SEIZMET G 0.5 FORTE", "description": "SEIZMET G0.5 FORTE is a powerful oral antidiabetic medication formulated with a combination of glimepiride and metformin hydrochloride. This dual-action therapy is specifically designed for patients with type 2 diabetes mellitus who are unable to control their blood sugar levels with diet and exercise alone. The combination works in synergy to manage blood glucose effectively, reduce insulin resistance, and improve overall glycemic control.\n\nGlimepiride and metformin hydrochloride tablets are a combination medication used to treat type 2 diabetes. They work by helping the pancreas release more insulin and by reducing the amount of sugar produced by the liver, while also making the body more sensitive to insulin.\n\nWhat is SEIZMET G0.5 FORTE?\nSEIZMET G0.5 FORTE contains two active ingredients:\n\nGlimepiride (0.5 mg): A sulfonylurea class drug that stimulates the beta cells of the pancreas to release insulin.\n\nMetformin Hydrochloride: A biguanide that works primarily by suppressing hepatic glucose production and increasing insulin sensitivity in muscles.\n\nTogether, this combination addresses both insulin deficiency and resistance—two key factors in type 2 diabetes.\n\nUses of SEIZMET G0.5 FORTE:\n\nEffective in managing type 2 diabetes mellitus\n\nHelps in reducing fasting and postprandial blood glucose levels\n\nUsed as monotherapy or in combination with other antidiabetic agents\n\nReduces the risk of diabetic complications such as nephropathy, retinopathy, and cardiovascular disease\n\nSide Effects of SEIZMET G0.5 FORTE:\nLike all medications, glimepiride and metformin hydrochloride tablets may cause side effects in some patients. Common side effects include:\n\nNausea or vomiting\n\nDiarrhea\n\nHypoglycemia (low blood sugar)\n\nHeadache\n\nDizziness\n\nMetallic taste in the mouth\n\nAbdominal discomfort\n\nIn rare cases, it may cause lactic acidosis, a serious condition related to metformin accumulation.\n\nPrecautions Before Using SEIZMET G0.5 FORTE:\n\nAlways take the medication exactly as prescribed by your doctor.\n\nInform your physician if you have a history of liver or kidney disorders, heart disease, or alcohol abuse.\n\nAvoid excessive alcohol consumption while on this medication as it increases the risk of lactic acidosis.\n\nNot recommended for patients with type 1 diabetes or diabetic ketoacidosis.\n\nRegularly monitor your blood sugar and kidney function.\n\nThis medicine should be used during pregnancy only if absolutely necessary and under medical supervision.\n\nDrug Interactions: What Drugs Interact with SEIZMET G0.5 FORTE?\nCertain medications can interact with glimepiride and metformin, affecting their efficacy or increasing the risk of side effects. These include:\n\nBeta-blockers (e.g., propranolol) – may mask hypoglycemia symptoms\n\nDiuretics – may impair blood sugar control\n\nACE inhibitors – may increase the blood glucose-lowering effect\n\nCorticosteroids – may reduce the effectiveness of the medication\n\nAntipsychotics (e.g., olanzapine)\n\nAlcohol – increases the risk of lactic acidosis\n\nCimetidine – may raise metformin levels in the body\n\nAlways inform your healthcare provider about all medications, supplements, or herbal products you are taking.\n\nConclusion:\nSEIZMET G0.5 FORTE is a trusted, effective choice for managing type 2 diabetes, offering the combined benefits of glimepiride and metformin hydrochloride tablets. With dual mechanisms—enhancing insulin secretion and improving insulin sensitivity—it delivers comprehensive glycemic control. When taken as directed and with regular monitoring, SEIZMET G0.5 FORTE can be a valuable part of a diabetic patient’s treatment regimen, contributing to a healthier, more balanced life.\n\nFor best results, pair this medication with a proper diet, regular physical activity, and periodic blood glucose testing. Always consult your healthcare provider for personalized advice.", "price": 125.0, "discountamount": 38.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2151, "imageuri": "https://productimages.withfloats.com/actual/68822dd8296c4d19d55e8535.png", "tileimageuri": "https://productimages.withfloats.com/tile/68822dd8296c4d19d55e8535.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-07-24T12:57:55.385Z", "updatedon": "2025-07-24T12:57:55.385Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/seizmet-g-0-5-forte/2151", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "glimepiride and metformin hydrochloride tablets", "category": "DIABETIC RANGE", "tags": [ "glimepiride and metformin hydrochloride tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }